<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322815</url>
  </required_header>
  <id_info>
    <org_study_id>GI-4000-05</org_study_id>
    <nct_id>NCT01322815</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI</brief_title>
  <official_title>A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI in Patients With Ras Mutant Positive Metastatic Colorectal Cancer, Either Newly Diagnosed or Previously Treated.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlobeImmune</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of GI-4000 and see what effects (good and
      bad) it has against cancer over time. This study is also being done to measure the immune
      response to GI-4000. Study drug will be given in addition to a standard of care which is a
      standard therapy given to patients with your type of cancer (colon).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject visits will occur 1-4 weeks prior to initiation of GI-4000, then

        -  In newly diagnosed (Group A) patients, at every FOLFOX/FOLFIRI plus bevacizumab visit,
           bevacizumab and GI-4000 dosing visit, GI-4000 dosing visit and then quarterly after
           completion of therapy

        -  In patients with stable disease who have completed a first line therapy with an
           oxaliplatin or irinotecan plus fluoropyrimidine and bevacizumab containing regimen
           (Group B), at every bevacizumab and GI-4000 dosing visit, GI-4000 dosing visit and then
           quarterly after completion of therapy

      Group A patients (N=26) will be enrolled into the study prior to the initiation of first line
      therapy with bevacizumab plus either FOLFOX (N=13) or FOLFIRI (N=13)

        -  Subjects will receive 1 40 yeast units (YU) dose of GI-4000 prior to initiation of
           FOLFOX or FOLFIRI plus bevacizumab, then intercycle doses of GI-4000 will be given 7
           days after each cycle while first line therapy is given (up to 8 cycles)

        -  After completion of first line therapy, subjects will enter the maintenance phase in
           which bevacizumab and GI-4000 will be given concurrently every 2 weeks for as long as
           therapy can be tolerated or until progression

        -  If a subject discontinues bevacizumab therapy due to intolerance, the subject will
           continue GI-4000 every 2 weeks until progression, intolerance or withdrawal from the
           study

      Group B patients (N=26) with stable disease who have completed a first line therapy with an
      oxaliplatin or irinotecan plus fluoropyrimidine and bevacizumab containing regimen ) will
      enter the trial prior to receiving therapy with bevacizumab

        -  Subjects will receive 40 yeast unit (YU) GI-4000 concurrently with each bevacizumab dose
           for as long as therapy can be tolerated or until progression

        -  If a subject discontinues bevacizumab therapy due to intolerance, the subject will
           continue GI-4000 every 2 weeks until progression, intolerance or withdrawal from the
           study
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual rate
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)</measure>
    <time_frame>4 Months for patients who had undergone prior 1st-line therapy, and 10 months for previously untreated patients</time_frame>
    <description>Clinical benefit rate is defined as the proportion of patients alive and free of progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients), assessed from first treatment with GI-4000. Progression is defined as CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of the target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of the target lesions; or SD (stable disease) = small changes that do not meet the above criteria.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and GI-4000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI-4000 and bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy and GI-4000</intervention_name>
    <description>Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks</description>
    <arm_group_label>Chemotherapy and GI-4000</arm_group_label>
    <other_name>5-fluorouracil (5-FU), leucovorin. oxaliplatin</other_name>
    <other_name>5-fluorouracil (5-FU), leucovorin, irinotecan</other_name>
    <other_name>avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks</description>
    <arm_group_label>GI-4000 and bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of metastatic colorectal cancer
             with a Ras mutation

          -  Measurable or evaluable disease

          -  No prior therapy fore metastatic disease except for group A: &gt; 6 months since
             completion of adjuvant therapy and Group B: those patients who enroll just after
             completing bevacizumab plus FOLFOX or FOLFIRI

          -  Anticipated survival of at least 6 months

          -  Ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Ability to maintain weight

          -  Normal organ and marrow function

          -  Women of child-bearing potential and men must agree to avoid pregnancy or fathering a
             child for the duration of study participation and for 6 months after the final
             scheduled study visit.

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior chemotherapy other than that listed in inclusion criteria

          -  Receiving any other investigational agent

          -  Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple
             sclerosis

          -  History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of
             FOLFOX or FOLFIRI

          -  Concurrent and chronic therapy with corticosteroids or any other immunosuppressive
             drugs

          -  Uncontrolled hypertension, unstable angina, congestive heart failure, peripheral
             vascular disease, serious cardiac arrythmias requiring medication

          -  History of heart attack or stroke within 6 months before enrollment

          -  History of intra-abdominal abscess, abdominal fistula, gastrointestinal perforation,
             or active peptic ulcer disease

          -  Bleeding disorder or coagulopathy

          -  Serious non-healing wound, ulcer or bone fracture

          -  Major surgical procedure, open biopsy, or traumatic injury within 4 weeks prior to
             enrollment or anticipation of need for surgery during the study

          -  Known active infection with HIV, hepatitis B or C

          -  History of splenectomy

          -  History of Crohn's disease or ulcerative colitis

          -  History of organ transplantation

          -  Evidence of immunodeficiency or immune suppression

          -  Any Autoimmune disease

          -  Active infection

          -  Concurrent malignancy

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Marshall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <results_first_submitted>April 29, 2016</results_first_submitted>
  <results_first_submitted_qc>July 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2016</results_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy and GI-4000</title>
          <description>Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks
chemotherapy and GI-4000: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>GI-4000 and Bevacizumab</title>
          <description>maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
GI-4000: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with RAS mutant positive metastatic colorectal cancer (CRC), either having received prior 1st-line therapy with an oxaliplatin or irinotecan plus fluoropyrimidine and bevacizumab containing regimen, or no prior therapy.</population>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy and GI-4000</title>
          <description>Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks
chemotherapy and GI-4000: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>GI-4000 and Bevacizumab</title>
          <description>maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
GI-4000: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="35" upper_limit="71"/>
                    <measurement group_id="B2" value="45" lower_limit="42" upper_limit="51"/>
                    <measurement group_id="B3" value="45" lower_limit="35" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior treatment status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prior 1st-line therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No prior therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)</title>
        <description>Clinical benefit rate is defined as the proportion of patients alive and free of progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients), assessed from first treatment with GI-4000. Progression is defined as CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of the target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of the target lesions; or SD (stable disease) = small changes that do not meet the above criteria.</description>
        <time_frame>4 Months for patients who had undergone prior 1st-line therapy, and 10 months for previously untreated patients</time_frame>
        <population>Patients with RAS mutant positive metastatic colorectal cancer (CRC), either newly diagnosed, or having completed first line therapy with an oxaliplatin or irinotecan plus fluoropyrimidine and bevacizumab containing regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy and GI-4000</title>
            <description>Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks
chemotherapy and GI-4000: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>GI-4000 and Bevacizumab</title>
            <description>maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
GI-4000: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients)</title>
          <description>Clinical benefit rate is defined as the proportion of patients alive and free of progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients), assessed from first treatment with GI-4000. Progression is defined as CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of the target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of the target lesions; or SD (stable disease) = small changes that do not meet the above criteria.</description>
          <population>Patients with RAS mutant positive metastatic colorectal cancer (CRC), either newly diagnosed, or having completed first line therapy with an oxaliplatin or irinotecan plus fluoropyrimidine and bevacizumab containing regimen.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From 48 to 739 days: as long as each individual patient was on study (from Nov 2010 until Sep 2013)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy and GI-4000</title>
          <description>Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks
chemotherapy and GI-4000: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>GI-4000 and Bevacizumab</title>
          <description>maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
GI-4000: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>low neutrophil count</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Unlikely related to GI-4000. Probably related to chemotherapy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis</sub_title>
                <description>Unlikely related to GI-4000. Probably related to chemotherapy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vaginismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epitaxis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John L Marshall</name_or_title>
      <organization>Ruesch Center at Georgetown Lombardi</organization>
      <phone>202.444.7064</phone>
      <email>marshalj@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

